Preview Mode Links will not work in preview mode

Substantial Matters: Life & Science of Parkinson’s


In Substantial Matters: Life & Science of Parkinson’s, host Dan Keller, PhD, interviews Parkinson’s experts to highlight treatments and techniques that can help you live a better life now, as well as research that can bring a better tomorrow. Episodes focus topics relevant to your daily life, including new levodopa delivery methods, exercise, clinical trials, nutrition and more! Learn more about our episodes and speakers at parkinson.org/Podcast. Follow and rate us on your favorite podcast platform to be notified when there’s a new episode! Let us know what other topics you would like us to cover by visiting parkinson.org/feedback.

Sep 8, 2020

Clinical studies, studies that involve people, first use healthy people to test a drug’s safety and then use people with a disease or condition to prove that the drug works as intended. They are essential for bringing any new therapy to the public. Getting U.S. Food and Drug Administration approval for devices require rigorous studies, as well. Recruiting enough people to participate is often a long process, and for trials that may go on for a year or more, retaining people in the studies is often a challenge. People may get bored, find multiple study visits burdensome, have an adverse reaction to a drug being tested, move away, or drop out for a multitude of other reasons. If too many people discontinue the study, it will not have enough statistical ”power” to give a meaningful answer when the data are analyzed. Christine Hunter, BSN, RN, Research Director of the Parkinson’s Disease Center and Movement Disorders Clinic at Baylor College of Medicine in Houston, a Parkinson’s Foundation Center of Excellence, describes how her center finds people with Parkinson’s disease who may want to participate in trials, what factors drive retention in trials, and ways to facilitate retention.